Chimeric antigen receptor (CAR) T cell therapy has achieved unprecedented success in hematologic malignancies, yet its application in solid tumors remains fraught with challenges. Key barriers include antigen heterogeneity, limited tumor infiltration, and most critically, the profoundly immunosuppressive tumor microenvironment (TME). This editorial synthesizes current research to detail the multifaceted suppressive effects of the TME on CAR-T cells, reviews innovative strategies being developed to overcome these barriers, and discusses the future trajectory of CAR-T therapy for solid tumors.

The TME presents a composite barrier to CAR-T cell efficacy, integrating physical, immunological, and metabolic obstacles [1]. Physically, solid tumors are characterized by a dense extracellular matrix (ECM) and aberrant vasculature, which severely impede CAR-T cell infiltration. Cancer-associated fibroblasts (CAFs) secrete components like collagen and hyaluronic acid, creating a rigid stromal network that blocks access to the tumor core, while abnormal blood vessels hinder both nutrient delivery and immune cell extravasation [2,3].

Immunologically, the TME is enriched with suppressive cells and cytokines that drive CAR-T cell exhaustion and dysfunction. Regulatory T cells (Tregs), which accumulate in the TME, inhibit cytotoxic CD8? T cell function via direct contact, secretion of inhibitory cytokines (e.g., IL-10, TGF-β), or granzyme/perforin-mediated lysis [4]. Similarly, tumor-associated macrophages (TAMs) predominantly adopt a pro-tumor M2 phenotype. These M2 TAMs secrete immunosuppressive factors (e.g., IL-10, TGF-β, Arg1), recruit Tregs, and actively suppress T cell-mediated immunity, thereby promoting tumor progression [5]. Critically, these mechanisms that suppress endogenous T cells are equally effective against engineered CAR-T cells, severely constraining their effector functions.

To enhance tumor infiltration, strategies targeting the tumor vasculature have been explored. Vascular abnormalities, often driven by VEGF overexpression, directly hinder CAR-T cell extravasation [1]. Consequently, VEGF blockade has emerged as a promising approach. Animal studies show that anti-VEGF strategies can increase tumor-infiltrating T cells and improve survival [6]. Building on this, the development of CAR-T cells targeting VEGFR1 and VEGFR2 has demonstrated potent anti-tumor and anti-angiogenic effects in preclinical models [7–9]. However, clinical translation has been challenging, as evidenced by a trial of VEGFR2-targeted CAR-T cells where only 1 of 24 patients achieved a partial response (NCT01218867), highlighting the need for more optimized strategies.

Combination therapies represent another avenue to modulate the TME. For instance, combining CAR-T cells with FLASH radiotherapy (ultrahigh-dose-rate delivery at ≥40 Gy/s) has shown superior synergistic efficacy in a medulloblastoma model. Research indicates that FLASH RT reprograms the TME by downregulating pro-tumor oxidative pathways, shifting macrophages from an M2 to an M1 phenotype, and sensitizing tumor cells to GD2 CAR-T cells, thereby achieving potent therapeutic effects while sparing normal tissue [10].

To directly counteract TME-induced dysfunction, "armored" CAR-T cells engineered to overexpress cytokines have been developed. For example, HER2-targeted CAR-T cells engineered to express IL-10 (IL-10 HER2 CAR-T) showed improved mitochondrial fitness (via enhanced OXPHOS), reduced exhaustion, and a stem-like memory phenotype, leading to enhanced tumor killing in models where conventional CAR-T cells failed [11]. This strategy, termed TRUCK (T cells redirected for universal cytokine-mediated killing), is a significant engineering approach, with similar efforts focusing on cytokines like IL-2, IL-7, and IL-15 [12].

A major challenge for armored CAR-T cells is systemic toxicity from constitutive transgene expression. An innovative solution involves using CRISPR knock-in to place cytokine genes (e.g., IL-12) under the control of endogenous, tumor-restricted promoters (e.g., NR4A2, RGS16). These promoters are activated primarily upon antigen stimulation at the tumor site. This approach enables localized cytokine delivery, which drives potent anti-tumor immunity and epitope spreading while avoiding systemic toxicity, as demonstrated in preclinical models [13].

The immunosuppressive TME remains a formidable barrier, but the strategies outlined here, ranging from vascular normalization and combination therapies to intelligently engineered CAR-T cells represent a concerted assault on this "peak." The field is moving beyond simply overcoming suppression towards actively reprogramming the TME into a permissive state. Future success will likely hinge on the precise spatial and temporal control of therapeutic payloads, the development of more predictive preclinical models, and the design of smarter clinical trials that prioritize biomarker-driven patient selection. While the gap between hematologic and solid tumor efficacy is still significant, the convergence of immunology, gene editing, and bioengineering continues to fuel tangible progress, bringing renewed hope for patients with solid tumors.